1. Home
  2. CANF vs AWX Comparison

CANF vs AWX Comparison

Compare CANF & AWX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • AWX
  • Stock Information
  • Founded
  • CANF 1994
  • AWX 1998
  • Country
  • CANF Israel
  • AWX United States
  • Employees
  • CANF N/A
  • AWX N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • AWX Environmental Services
  • Sector
  • CANF Health Care
  • AWX Utilities
  • Exchange
  • CANF Nasdaq
  • AWX Nasdaq
  • Market Cap
  • CANF 9.6M
  • AWX 10.1M
  • IPO Year
  • CANF N/A
  • AWX 1998
  • Fundamental
  • Price
  • CANF $0.50
  • AWX $2.67
  • Analyst Decision
  • CANF Strong Buy
  • AWX
  • Analyst Count
  • CANF 2
  • AWX 0
  • Target Price
  • CANF $14.50
  • AWX N/A
  • AVG Volume (30 Days)
  • CANF 280.9K
  • AWX 595.6K
  • Earning Date
  • CANF 11-27-2025
  • AWX 11-07-2025
  • Dividend Yield
  • CANF N/A
  • AWX N/A
  • EPS Growth
  • CANF N/A
  • AWX 306.94
  • EPS
  • CANF N/A
  • AWX 0.03
  • Revenue
  • CANF $560,000.00
  • AWX $78,200,000.00
  • Revenue This Year
  • CANF $461.72
  • AWX N/A
  • Revenue Next Year
  • CANF N/A
  • AWX N/A
  • P/E Ratio
  • CANF N/A
  • AWX $85.91
  • Revenue Growth
  • CANF N/A
  • AWX N/A
  • 52 Week Low
  • CANF $0.47
  • AWX $2.10
  • 52 Week High
  • CANF $3.02
  • AWX $5.43
  • Technical
  • Relative Strength Index (RSI)
  • CANF 31.15
  • AWX 48.65
  • Support Level
  • CANF $0.49
  • AWX $2.50
  • Resistance Level
  • CANF $0.55
  • AWX $5.43
  • Average True Range (ATR)
  • CANF 0.03
  • AWX 0.34
  • MACD
  • CANF -0.00
  • AWX -0.03
  • Stochastic Oscillator
  • CANF 13.94
  • AWX 4.83

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About AWX Avalon Holdings Corporation

Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.

Share on Social Networks: